# Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma

> **NCT01327521** · PHASE3 · WITHDRAWN · sponsor: **Albert Koong**

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DEVICE:** CyberKnife
- **PROCEDURE:** TACE
- **DRUG:** CT Contrast
- **DRUG:** doxorubicin
- **DRUG:** Epirubicin
- **DRUG:** 5-fluorouracil
- **DRUG:** Mitomycin C
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin
- **DEVICE:** SMANCS

## Key facts

- **NCT ID:** NCT01327521
- **Lead sponsor:** Albert Koong
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-02
- **Primary completion:** 2014-02
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Accrual below target levels
- **Last updated:** 2012-06-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01327521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01327521, "Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01327521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*